Deep Vein Thrombosis - A Drug Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--Sep 26, 2018--Technavio has announced their latest . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of deep vein thrombosis. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005932/en/
Technavio has published a new report on the drug development pipeline for the treatment of deep vein thrombosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Deep vein thrombosis: An overview
Deep vein thrombosis (DVT) is the formation of blood clot in a vein deep in the body. Most of the deep vein clots occur in the legs. It can cause pain and redness in the legs and swelling in the lower leg, ankle, and foot. It is a part of venous thromboembolism (VTE), in which the blood clots formed in the deep veins of the leg move to the lungs and block a blood vessel. This leads to low oxygen levels in the blood, causing damage to the lungs known as pulmonary embolism.
DVT is a common disease that can lead to complications such as pulmonary embolism and death. The approach to the diagnosis of DVT has evolved over the years. Usually, anticoagulation therapy is used for the treatment of DVT, whereas procedures such as thrombolysis and placement of inferior vena cava filters are reserved for a special situation.
Deep vein thrombosis: Segmentation of pipeline molecules
Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with close to 43% of the pipeline molecules administered through this mode.
Between companies and institutions, institutions led the drug development space for the treatment of deep vein thrombosis. Some of the key players include Genentech, ST Pharm, TeaRx, and Verseon.
Some of the key topics covered in the report include:
1. Scope of the Report
2. Regulatory Framework
3. Drug Development LandscapeDrugs under development
4. Drug Development StrategiesTherapies employed Route of administration Therapeutic modality Mechanism of action
5. Recruitment StrategiesGeographical coverage Recruitment status Gender Age
6. Key CompaniesType of players Company overview
7. Discontinued and Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005932/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/26/2018 03:16 PM/DISC: 09/26/2018 03:15 PM